BIOS

Robert Pearl is the former CEO @ The Permanente Medical Group (1999-2017), the nation’s largest medical group, and former president of The Mid-Atlantic Permanente Medical Group (2009-2017). In these roles he led 10,000 physicians, 38,000 staff and was responsible for the nationally recognized medical care of 5 million Kaiser Permanente members on the west and east coasts. Dr. Pearl is nationally recognized as a physician leader on healthcare delivery. He hosts a popular podcast called Fixing Healthcare and is author of a Washington Post Bestseller: “Mistreated: why we think we’re getting good healthcare -- and why we’re usually wrong” (he has generously donated all the proceeds from his book to Doctors Without Borders). More recently, he has started a new weekly podcast - “Coronavirus: The Truth.” He writes regularly on Forbes and teaches at both the Stanford School of Medicine and Stanford Graduate School of Business. Dr. Pearl received his medical degree at Yale and completed a plastic surgery residency at Stanford. Visit his website to learn more.Technology companies have increasingly focused on the healthcare system, and many are excited by their potential to drive change, decrease costs, and improve outcomes. Dr. Robert Pearl discusses hype versus reality in healthcare delivery innovation and how tech can help - but also hurt.Topics:How Kaiser Permanente has become a leader in quality, access, and priceThe role of tech in the fee-for-service versus capitation debateDisruption of the fee-for-service system coming from HAVEN, self-insured employers, and off-shore care partnershipsHype versus reality in tech: how tech often approaches healthcare innovation wrongThe problem with wearablesMisaligned incentives within healthcare and techThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Rob Chess is a successful and esteemed serial biotech entrepreneur and executive. His resume is incredibly long and impressive. He is the Chairman of Nektar Therapeutics (NASDAQ: NKTR), a multi-billion dollar market cap company, where he was previously President and CEO. He is co-founder and Board member (until very recently the Chairman) of Biota Technologies, which uses DNA sequencing to optimize oil and gas production. He is a Lead Director at Twist Biosciences (NASDAQ: TWST), a public company that produces synthetic genes using an innovative high-throughput silicon-based manufacturing process. He was previously Chairman and CEO of OPX Biotechnologies, a renewable chemicals company that was sold to Cargill, and co-founder and President of Penederm, a dermatology company that went public and was acquired by Mylan Laboratories. He served in the White House in the first Bush administration, teaches at the Stanford business school, and is on the board of trustees at CalTech, and sits on the board of various other companies and organizations, among many other accomplishments.The biopharma industry is undergoing immense change as there are exciting advancements in technology and life sciences, amidst a constantly changing structural environment. Rob Chess discusses keys for success for founders and executives and explores some key trends involving scale, platforms, financing, discovery, and payment reform within biopharma.Topics:Keys to success as a founder or executive in biotechThe cyclical nature of platforms, products, and financing in biotech as an industryScale in biopharmaThe impact of tech-enabled services on biopharmaDirect-to-consumer biopharmaEroom’s Law and drug discoveryAcademia vs industry for life sciences innovationBusiness model problems that belie the lack of successes in diagnosticsIncentive structures in healthcare and how to align themBusiness school and management in healthcare and biopharmaPayment reform for specialty pharmaceuticalsWhy go into healthcare?Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Ian Tong is Chief Medical Officer @ Doctor On Demand. He is also currently Clinical Assistant Professor (Affiliated) at Stanford University Medical School. Ian has spent his career working to improve access to high quality care and brings this dedication to his work at Doctor On Demand.Prior to joining Doctor On Demand, Ian held several medical leadership roles. He served as Stanford Internal Medicine Chief Resident; Co-Medical Director of the Arbor Free Clinic; and Founder and Medical Director of The Health Resource Initiative for Veterans Everywhere (THRIVE) at the VA Palo Alto Health Care System, which was honored in 2008 by the U.S. Secretary of Veterans Affairs with the Award for Outstanding Achievement in Service to Homeless Veterans. Before becoming Chief Medical Officer, Ian served as Medical Director at Doctor On Demand.Ian is a National Collegiate Champion in Rugby at the University of California at Berkeley and was named to the All American Team in 1994. He graduated with a BA in English. He earned a medical degree from The University of Chicago – Pritzker and completed residency and Chief residency at Stanford Hospital and Clinics. He is board certified in Internal Medicine.Ian lives in the San Francisco Bay Area with his wife and three children. He is most proud of the relationships he has built working alongside his family, friends, teammates, students and colleagues to positively impact the lives of others.The COVID-19 pandemic is creating an inflection point in healthcare delivery and innovation. Telemedicine is playing a central role in combating the novel coronavirus outbreak, and the telehealth industry will emerge from the pandemic with new winners, losers, and structural changes.Topics:State of the pandemic and the role of telemedicine in combating itThe impact of COVID on the telehealth industryTelemedicine winners and losers in aftermath of COVID: from point solutions to integrated longitudinal careThe power of retail clinics both during the pandemic and long term in telehealth and care deliveryStructural and policy changes needed for future pandemics and for the advancement of telemedicineThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

BIOS Podcast brings together cutting-edge insights from Life Science industry leaders at the forefront innovation. Join us in hearing from Founders, Investors, Professors, & Pharma operating at the intersection of Technology & Biology. By Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health. Learn more @ BIOS.community / Alix.vc